Organon Launches “Her Plan is Her Power,” a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist

Rhea-AI Summary

Organon (NYSE: OGN) has launched a global initiative named “Her Plan is Her Power” with a funding of $30 million aimed at addressing unplanned pregnancies, which affect approximately 121 million women and girls yearly. This initiative extends from the previous FP2030 commitment and focuses on improving access to contraceptive services. The multi-year program (2023-2025) includes collaborations with UNFPA and grants to local organizations across 13 countries. The initiative was announced on International Women’s Day, highlighting the urgent need for public health solutions in women’s reproductive health.

Positive

• Launch of the ‘Her Plan is Her Power’ initiative to tackle unplanned pregnancies.
• Funding of $30 million to support global health initiatives.
• Collaboration with UNFPA to enhance sexual and reproductive health services.
• Grants program to empower local organizations in 13 countries.

Negative

• None.

Building on Organon’s Prior FP2030 Commitment, the Company Announces $30 Million in New Funding to Fuel Global Action and Community-Driven Solutions Needed by the 121 Million Women and Girls Who Experience Unplanned Pregnancies Each Year

JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company focused on improving women’s health, today announced the launch of a new global initiative, “Her Plan is Her Power,” to accelerate progress toward addressing the public health crisis of unplanned pregnancy. Annually, nearly 50% of pregnancies (approximately 121 million) around the world are estimated to be unplanned, leading to health risks and reduced educational and employment opportunities for mother and child – challenges which can span generations.

Unplanned pregnancies are in part caused by a lack of access to contraceptive information and services. Globally, of the 257 million women who want to avoid pregnancy, almost 67% are not using any contraceptive method. In response, Organon’s multi-year effort (2023-2025) builds on previous programming launched in 2022 through the “Her Promise” ESG platform. This new effort includes a portfolio of programs, collaborations and investments designed to fuel public health solutions, address inequities, and accelerate progress to help ensure women have the power to plan their future.

The $30 million “Her Plan is Her Power” initiative aims to address and overcome gaps and barriers to reduce unplanned pregnancies and empower women and girls when it comes to their sexual and reproductive health (SRH). It builds on existing company initiatives, with new funding to support:

• A planned three-pronged collaboration with UNFPA, the United Nations sexual and reproductive health agency, to help reduce unplanned pregnancies focused on innovation, access and education, and financing and sustainability. Initial projects are planned to support the Equalizer: UNFPA Accelerator Fund, through the establishment of an innovation challenge to empower young people by increasing access to financing and training to enable innovations for SRH information, services and commodities; enhancing a digital SRH knowledge solution with ethical artificial intelligence capabilities to give information and analytics to frontline healthcare workers in low-resource settings; and support for the Equity 2030 Alliance to accelerate actions to normalize gender equity in science and technology with a focus on SRH and women-focused solutions.
• Inaugural launch of a global grants program that provides resources to organizations working in communities to create a local response and empower people when it comes to reducing unplanned pregnancies and taking control of their reproductive health. The first cohort of grantees includes organizations across 13 countries including Dominican Republic, South Korea, Germany, and Thailand.
• New funding and product donations to help improve access and outcomes related to unplanned pregnancy in select communities in the US. Initial planned NGO partners include Direct Relief and Power to Decide, with additional US-based organizations and communities to be announced later this year.

“Empowering women with broad contraceptive access and education is a fundamental driver of equity and helping women decide when – and if – they decide to start a family,” said Kevin Ali, CEO of Organon. “Organon is proud to launch ‘Her Plan is Her Power’ and work with others to focus our resources and target responses to help ensure all women and girls can plan their future.”

This announcement comes on International Women’s Day and on the sidelines of the 67th session of the United Nations Commission on the Status of Women, to raise awareness and spur action, because in this complex environment, there has never been a more critical moment to stand – and act – with her.

“UNFPA is very excited to be working with Organon to advance sexual and reproductive health and rights and choices,” says Ian McFarlane, the Director of the Division for Communications and Strategic Partnerships at UNFPA. “The staggering number of unintended pregnancies that occur globally each year – nearly half of all pregnancies – require the power of public-private collaboration. We look forward to continuing to build upon our efforts to help improve the lives of women and girls around the world.”

Organon is working to ensure that all women and girls achieve the full potential of their promise through better health. In 2022, Organon made a commitment to help prevent 120 million unplanned pregnancies in the world’s least-developed countries by 2030 as part of FP2030. Through “Her Plan is Her Power” the company will further accelerate progress towards this goal by working with global and local organizations across geographies with a focus on innovation, education, access, and advocacy.

About Organon

Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon offers more than 60 medicines and products in women’s health in addition to a growing biosimilars business and a large franchise of established medicines across a range of therapeutic areas. Organon’s existing products produce strong cash flows that support investments in innovation and future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit https://www.organon.com/ and connect with us on LinkedIn, Instagram, Twitter and Facebook.

Forward-Looking Statement

Except for historical information herein, this press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about Organon’s launch of the “Her Plan is Her Power” global initiative. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission ("SEC"), including the company’s Annual Report on Form 10-K for the year ended December 31, 2022, available at the SEC’s Internet site (www.sec.gov).

View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005176/en/

Media:

Karissa Peer

(614) 314-8094

Joanna Breitstein

(347) 820-4046

Investor:

Jennifer Halchak

(201) 275-2711

Alex Arzeno

(203) 550-3972

Source: Organon & Co.

FAQ

What is Organon's new initiative ‘Her Plan is Her Power’ about?

Organon's ‘Her Plan is Her Power’ initiative aims to address unplanned pregnancies globally by improving access to contraceptive services with a funding of $30 million.

How much funding has Organon committed to its new initiative?

Organon has committed $30 million to the ‘Her Plan is Her Power’ initiative.

What is the main goal of Organon’s ‘Her Plan is Her Power’ initiative?

The main goal is to reduce unplanned pregnancies, which affect around 121 million women and girls each year.

Which organization is partnering with Organon on this initiative?

Organon is collaborating with UNFPA, the United Nations sexual and reproductive health agency.

When was the ‘Her Plan is Her Power’ initiative announced?

The initiative was announced on International Women’s Day.

In how many countries will the grants program operate under ‘Her Plan is Her Power’?

The grants program will operate in 13 countries.